Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice

(2012) Brett H. Simmons et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting NRAS in Melanoma

(2012) Fergal C. Kelleher et al.   CANCER JOURNAL

Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

(2012) P. J. Roberts et al.   CLINICAL CANCER RESEARCH

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

(2012) Erika von Euw et al.   Molecular Cancer

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

(2012) Lawrence N Kwong et al.   NATURE MEDICINE

mTORC1 inhibition and ECM–cell adhesion-independent drug resistance via PI3K–AKT and PI3K–RAS–MAPK feedback loops

(2012) Karina Galoian et al.   TUMOR BIOLOGY

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

(2012) Eric A. Collisson et al.   Cancer Discovery

Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax

(2011) M. Espona-Fiedler et al.   BIOCHEMICAL PHARMACOLOGY

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

(2011) M. K. Kiessling et al.   BLOOD

In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer

(2011) K. M. Kinross et al.   MOLECULAR CANCER THERAPEUTICS

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

(2011) Mohammad Atefi et al.   PLoS One

4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

(2010) Qing-Bai She et al.   CANCER CELL

Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation

(2010) P J Mishra et al.   ONCOGENE

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

(2009) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase

(2008) Dirk A. Heerding et al.   JOURNAL OF MEDICINAL CHEMISTRY